Covid 19 Research using Clinical Trials (Home Page)
Report for D007238: Infarction NIH
(Synonyms: Infarcti, Infarctio, Infarction)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug22 | 2D Telemedicine Wiki | 0.58 |
| drug195 | Blood Transfusion Wiki | 0.58 |
| drug1000 | Percutaneous Coronary Revascularization for STEMI Wiki | 0.58 |
| drug26 | 3D Telemedicine Wiki | 0.58 |
Correlated MeSH Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009203 | Myocardial Ischemia NIH | 0.77 |
| D000072657 | ST Elevation Myocardial Infarction NIH | 0.58 |
| D009206 | Myocardial NIH | 0.58 |
| D058186 | Acute Kidney Injury NIH | 0.19 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001658 | Myocardial infarction HPO | 0.58 |
| HP:0001919 | Acute kidney injury HPO | 0.24 |
There are 3 clinical trials
Clinical Trials
1 CSP #599 - Transfusion Trigger After Operations in High Cardiac Risk Patients (TOP)
The goal of the proposed study is to determine whether a liberal transfusion strategy (transfusion trigger at Hb < 10 gm/dl) in Veterans at high cardiac risk who undergo major open vascular and general surgery operations is associated with decreased risk of adverse postoperative outcomes compared to a restrictive transfusion strategy (transfusion trigger at Hb < 7 gm/dl).
NCT03229941 Myocardial Infarction Coronary Revascularization Acute Renal Failure Procedure: Blood Transfusion MeSH:Acute Kidney Injury Myocardial Infarction Infarction
HPO:Acute kidney injury Myocardial infarction
Primary Outcomes
Description: MI will be defined using the Third Universal Definition of Myocardial Infarction. Acute renal failure will be defined as Acute Kidney Injury stage III according to RIFLE criteria. Baseline creatinine will be considered the creatinine upon admission prior to the index operation. The above urine output criteria will be only used for patients who are in the ICU and have precise monitoring of their urinary output. For patients on the surgical floor only serum creatinine changes will be used for assessment of this endpoint. Coronary revascularization will be defined as a coronary artery bypass graft, or percutaneous coronary intervention (either angioplasty or stenting). Stroke will be defined as new unilateral neurological deficit that lasts for more than 24 hours, and is confirmed by a brain imaging modality (computed tomography or magnetic resonance imaging study) demonstrating new brain infarct.
Measure: A composite endpoint of all-cause post-randomization mortality, myocardial infarction (MI), coronary revascularization, acute renal failure, or post-randomization ischemic stroke up to 90 days after randomization. Time: 90 days after randomization
Secondary Outcomes
Description: Wound infection will be defined according to the Centers for Disease Control and Prevention (CDC) guidelines as a) positive wound culture, or b) drainage of pus from a wound, or c) suspicion of wound infection that was drained operatively.
Pneumonia will be defined according to the CDC definition as chest radiograph with new or progressive infiltrate, consolidation, cavitation, or pleural effusion and any of the following: new onset of purulent sputum or change in character of sputum, or organism isolated from blood culture, trans-tracheal aspirate, bronchial brushings, or biopsy.
Sepsis will be defined as a combination of two of the following systemic inflammatory response syndrome (SIRS) criteria, plus suspected or present source of infection. SIRS criteria will include the following: temperature greater than 38C, heart rate greater than 90 beats/min, WBC > 12,000 or < 4,000, or > 10% bands.
Measure: A composite endpoint of postoperative infectious complications at 90 days post-randomization: Infectious complications will include wound infections, pneumonia, and sepsis. Time: 90 days after randomization
Description: The diagnosis of cardiac arrhythmias will be based on EKG findings. Only arrhythmias that result in initiation of new treatment regimen (to include medications, implantable devices, or surgical intervention) during hospitalization will be recorded.
CHF will require at least one of the following symptoms or signs new or worsening: dyspnea at rest, orthopnea, or paroxysmal nocturnal dyspnea and radiological evidence of heart failure or worsening heart failure and increase/initiation of established treatment.
Cardiac arrest will be defined as the cessation of cardiac pump function activity that results in loss of consciousness and absence of circulating blood flow as evidenced by absent carotid pulse. Only episodes of cardiac arrest that are reversed will be collected under this endpoint. If they are not reversed the event will be categorized as death.
Measure: A composite endpoint of cardiac complications (other than MI) at 90 days post-randomization: Cardiac complications will include new cardiac arrhythmias that necessitate new treatment, new or worsening congestive heart failure (CHF), and cardiac arrest no Time: 90 days after randomization
Description: The investigators will determine vital status by telephoning participants after hospital discharge, by searching the electronic medical record and the National Death Index.
Measure: All-cause mortality at 1 year after randomization. Time: 12 months after randomization
Description: MI, coronary revascularization, acute renal failure, or postoperative ischemic stroke.
Measure: A composite endpoint of all-cause mortality, Time: 30 days after randomization
Description: Length of hospital stay
Measure: Length of hospital stay. Time: At hospital discharge, up to 1 year
Other Outcomes
Description: All cause postoperative mortality, Postoperative MI, Postoperative coronary revascularization, Postoperative stroke,Postoperative acute renal failure
Measure: The investigators will examine individual rates of the outcomes that consist of individual components of the primary endpoint. Time: 90 days after randomization
2 Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study
Primary Outcomes
Description: MI will be defined using the Third Universal Definition of Myocardial Infarction. Acute renal failure will be defined as Acute Kidney Injury stage III according to RIFLE criteria. Baseline creatinine will be considered the creatinine upon admission prior to the index operation. The above urine output criteria will be only used for patients who are in the ICU and have precise monitoring of their urinary output. For patients on the surgical floor only serum creatinine changes will be used for assessment of this endpoint. Coronary revascularization will be defined as a coronary artery bypass graft, or percutaneous coronary intervention (either angioplasty or stenting). Stroke will be defined as new unilateral neurological deficit that lasts for more than 24 hours, and is confirmed by a brain imaging modality (computed tomography or magnetic resonance imaging study) demonstrating new brain infarct.
Measure: A composite endpoint of all-cause post-randomization mortality, myocardial infarction (MI), coronary revascularization, acute renal failure, or post-randomization ischemic stroke up to 90 days after randomization. Time: 90 days after randomizationSecondary Outcomes
Description: Wound infection will be defined according to the Centers for Disease Control and Prevention (CDC) guidelines as a) positive wound culture, or b) drainage of pus from a wound, or c) suspicion of wound infection that was drained operatively. Pneumonia will be defined according to the CDC definition as chest radiograph with new or progressive infiltrate, consolidation, cavitation, or pleural effusion and any of the following: new onset of purulent sputum or change in character of sputum, or organism isolated from blood culture, trans-tracheal aspirate, bronchial brushings, or biopsy. Sepsis will be defined as a combination of two of the following systemic inflammatory response syndrome (SIRS) criteria, plus suspected or present source of infection. SIRS criteria will include the following: temperature greater than 38C, heart rate greater than 90 beats/min, WBC > 12,000 or < 4,000, or > 10% bands.
Measure: A composite endpoint of postoperative infectious complications at 90 days post-randomization: Infectious complications will include wound infections, pneumonia, and sepsis. Time: 90 days after randomizationDescription: The diagnosis of cardiac arrhythmias will be based on EKG findings. Only arrhythmias that result in initiation of new treatment regimen (to include medications, implantable devices, or surgical intervention) during hospitalization will be recorded. CHF will require at least one of the following symptoms or signs new or worsening: dyspnea at rest, orthopnea, or paroxysmal nocturnal dyspnea and radiological evidence of heart failure or worsening heart failure and increase/initiation of established treatment. Cardiac arrest will be defined as the cessation of cardiac pump function activity that results in loss of consciousness and absence of circulating blood flow as evidenced by absent carotid pulse. Only episodes of cardiac arrest that are reversed will be collected under this endpoint. If they are not reversed the event will be categorized as death.
Measure: A composite endpoint of cardiac complications (other than MI) at 90 days post-randomization: Cardiac complications will include new cardiac arrhythmias that necessitate new treatment, new or worsening congestive heart failure (CHF), and cardiac arrest no Time: 90 days after randomizationDescription: The investigators will determine vital status by telephoning participants after hospital discharge, by searching the electronic medical record and the National Death Index.
Measure: All-cause mortality at 1 year after randomization. Time: 12 months after randomizationDescription: MI, coronary revascularization, acute renal failure, or postoperative ischemic stroke.
Measure: A composite endpoint of all-cause mortality, Time: 30 days after randomizationDescription: Length of hospital stay
Measure: Length of hospital stay. Time: At hospital discharge, up to 1 yearOther Outcomes
Description: All cause postoperative mortality, Postoperative MI, Postoperative coronary revascularization, Postoperative stroke,Postoperative acute renal failure
Measure: The investigators will examine individual rates of the outcomes that consist of individual components of the primary endpoint. Time: 90 days after randomizationIn late December 2019, an emerging disease due to a novel coronavirus (named SARS-CoV-2) rapidly spread in China and outside. France is currently facing the COVID-19 wave with more than 131 863 confirmed cases and almost 25 201 deaths. Systems of care have been reorganized in an effort to preserve hospital bed capacity, resources, and avoid exposure of patients to the hospital environment where COVID-19 may be more prevalent. Therefore, elective procedures of catheterization and programmed hospitalizations have been delayed. However, a significant proportion of procedures within the catheterization laboratory such as ST-elevation myocardial infarction (STEMI), non ST elevation myocardial infarction or unstable angina are mandatory and cannot be postponed. Surprisingly, invasive cardiologist noticed a drop in STEMI volume without reliable data to confirm this impression. Furthermore, a recent single center report in Hong Kong pointed out longer delays of taking care when compared to patients with STEMI treated with percutaneous intervention the previous year. These data are at major concern because delay in seeking care or not seeking care could have detrimental impact on outcomes.
NCT04357314 Myocardial Infarction MeSH:Myocard Myocardial Infarction Infarction
HPO:Myocardial infarction
Primary Outcomes
Description: Compare the number of patients presenting to cardiology department with acute myocardial infarction in 2019 versus in 2020
Measure: Rates of patients presenting with acute myocardial infarction Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )
Secondary Outcomes
Description: Correlation between clinical patient profile and the degree of affection of regions by COVID-19
Measure: Patient profile during admission for acute myocardial infarction Time: 3 months (between March 1 to May 31
Description: Correlation between the delay between onset of symptoms - first medical contact - coronary angiography room and the degree of affection of regions by COVID-19
Measure: Medical care times analysis Time: 3 months (between March 1 to May 31)
Description: Correlation between the number of patients who underwent systemic thrombolysis and the degree of affection of regions by COVID-19
Measure: Proportion of patients who underwent systemic thrombolysis Time: 3 months (between March 1 to May 31)
Description: Number of patient admitted in cardiology department for acute myocardial infarction infected with COVID-19
Measure: Proportion of patients infected with COVID-19 Time: 3 months (between March 1 to May 31)
Description: Correlation between the fate of patient and the degree of affection of regions by COVID-19: Number of days in cardiology department, Left Ventricular Ejection Fraction at discharge, presence of hemodynamic complications, presence of mechanical complications, transfer to intensive care unit, infection with COVID-19 during hospitalization, living status at discharge
Measure: Clinical evolution of patients Time: 3 months (between March 1 to May 31)
3 International Study on Acute Coronary Syndromes - ST-segment Elevation Myocardial Infarction COVID 19
Primary Outcomes
Description: Compare the number of patients presenting to cardiology department with acute myocardial infarction in 2019 versus in 2020
Measure: Rates of patients presenting with acute myocardial infarction Time: 3 months (between March 1 to May 31, 2019 and between March 1 to May 31, 2020 )Secondary Outcomes
Description: Correlation between clinical patient profile and the degree of affection of regions by COVID-19
Measure: Patient profile during admission for acute myocardial infarction Time: 3 months (between March 1 to May 31Description: Correlation between the delay between onset of symptoms - first medical contact - coronary angiography room and the degree of affection of regions by COVID-19
Measure: Medical care times analysis Time: 3 months (between March 1 to May 31)Description: Correlation between the number of patients who underwent systemic thrombolysis and the degree of affection of regions by COVID-19
Measure: Proportion of patients who underwent systemic thrombolysis Time: 3 months (between March 1 to May 31)Description: Number of patient admitted in cardiology department for acute myocardial infarction infected with COVID-19
Measure: Proportion of patients infected with COVID-19 Time: 3 months (between March 1 to May 31)Description: Correlation between the fate of patient and the degree of affection of regions by COVID-19: Number of days in cardiology department, Left Ventricular Ejection Fraction at discharge, presence of hemodynamic complications, presence of mechanical complications, transfer to intensive care unit, infection with COVID-19 during hospitalization, living status at discharge
Measure: Clinical evolution of patients Time: 3 months (between March 1 to May 31)The ISACS STEMI COVID-19 has been established in response to the emerging outbreak of COVID-19 to provide a European overview to estimate the real impact of COVID-19 pandemic on treatment and outcome of STEMI by primary angioplasty, and to identify any potential category of patients at risk for delay to treatment or no presentation.
NCT04412655 ST Elevated Myocardial Infarction Undergoing Mechanical Reperfusion Device: Percutaneous Coronary Revascularization for STEMI MeSH:Myocardial Infarction ST Elevation Myocardial Infarction Infarction
HPO:Myocardial infarction
Primary Outcomes
Description: Number of patients undergoing primary angioplasty
Measure: Number of patients undergoing primary angioplasty Time: March April 2019 and 2020
Description: Number of patients undergoing primary angioplasty later 12 hours from symptoms onset;
Measure: Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset; Time: March April 2019 and 2020
Description: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission
Measure: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission Time: March April 2019 and 2020
Description: In-Hospital mortality
Measure: In-hospital mortality Time: March April 2019 and 2020
HPO Nodes
Primary Outcomes
Description: Number of patients undergoing primary angioplasty
Measure: Number of patients undergoing primary angioplasty Time: March April 2019 and 2020Description: Number of patients undergoing primary angioplasty later 12 hours from symptoms onset;
Measure: Number of patients undergoing primary angioplasty later than 12 hours from symptoms onset; Time: March April 2019 and 2020Description: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission
Measure: Number of patients undergoing primary angioplasty later than 30 minutes from PCI hospital admission Time: March April 2019 and 2020Description: In-Hospital mortality
Measure: In-hospital mortality Time: March April 2019 and 2020